Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the (a) accessibility and (b) availability of functional MRI scans.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Functional magnetic resonance imaging (MRI) scans can be taken on standard clinical MRI machines. However, whilst functional MRI requires specialised software to detect blood flow changes, the blood-oxygen-level-dependent signal, and sometimes extra equipment for stimuli, for instance goggles, it uses the same scanner hardware as structural MRI.
We are committed to transforming diagnostic services and will support the National Health Service to increase diagnostic capacity to meet the demand for diagnostic services, including MRI scanners.
The 2025 Spending Review confirmed over £6 billion of additional capital investment over five years across new diagnostic, elective, and urgent care capacity. This includes £600 million in capital funding for diagnostics in 2025/26 to support delivery of the NHS performance standards. This funding will deliver replacement of the oldest MRI scanners in community diagnostic centres and acute hospital settings, as well as delivering MRI acceleration software. Business cases for the locations of these are being considered for approval.
Capital investment will be targeted to locations where it will enable the additional activity required to deliver the return to referral to treatment and cancer constitutional standards promised, as well as considering local levels of deprivation so that investment supports efforts to reduce health inequalities.
Asked by: Mike Martin (Liberal Democrat - Tunbridge Wells)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact on patients with relapsed or refractory Mantle Cell Lymphoma of NICE’s draft decision not to recommend brexucabtagene autoleucel (Tecartus) for NHS use; and whether he plans to review the CAR‑T delivery tariff to ensure continued access to treatments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is currently re-evaluating brexucabtagene autoleucel to determine whether it can be recommended for routine National Health Service funding following a period of managed access through the Cancer Drugs Fund. NICE’s draft guidance, published in December, does not recommend it as a clinically and cost-effective use of NHS resources. The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients with mantle cell lymphoma will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
The CAR-T delivery tariff reflects the costs which the NHS incurs for delivering CAR-T therapy. The tariff was updated for the start of the 2024/25 financial year following a planned costing review involving all CAR-T providers in England. This enabled the tariff to be updated with the benefit of the significant delivery experience that can be drawn on having first routinely introduced CAR-T in the NHS in 2023. Other than considering an appropriate inflationary uplift on an annual basis, in line with usual practice, there are no plans to further review the tariff at this time. Other CAR-T therapies have been recommended for routine NHS adoption in England by NICE based on an assessment of clinical and cost effectiveness that reflects the existing CAR-T delivery tariff, most recently obecabtagene autoleucel for acute lymphoblastic leukaemia.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what treatments exist for those mantle cell lymphoma patients unable to access allogeneic stem cell transplants due to (1) ethnicity, (2) age, and (3) ethnicity and age.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A number of National Health Service treatment options are available for patients with mantle cell lymphoma, and may include:
- chemotherapy plus rituximab;
- autologous stem cell transplant;
- ibrutinib;
- zanubrutinib;
- brexucabtagene autoleucel, a type of chimeric antigen receptor T-cell therapy; and/or
- supportive care.
None of these treatments are precluded on the basis of ethnicity, age, or a combination of the two, but available options will be dependent on individual clinical circumstances and any prior treatment or treatments received.
Potential treatment options are also currently being appraised by the National Institute for Health and Care Excellence and therefore could be made available within England in the future, subject to positive recommendations on NHS adoption being reached. These are: Acalabrutinib with bendamustine and rituximab; and Ibrutinib with R-CHOP.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department are taking to ensure the effectiveness of cancer screening programmes in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England Screening and Immunisation Teams, including a dedicated team covering Thames Valley, work closely with providers and local partners to ensure cancer screening programmes are delivered in line with national standards for quality, safety and effectiveness.
At a local level, the NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board (ICB) works in partnership with NHS England, primary care, providers and the Thames Valley Cancer Alliance to support the delivery and uptake of cancer screening programmes across Buckingham and Bletchley. This includes ongoing monitoring of screening coverage and performance at place and practice level, identifying variation, and supporting action where uptake or performance falls below national standards.
At a national level, we recently announced that the NHS Bowel Cancer Screening Programme in England is lowering the faecal immunochemical test threshold from 120 micrograms of blood per gram of faeces to 80 micrograms of blood per gram of faeces. It is estimated that this change will detect approximately 600 additional bowel cancers early each year in England, approximately an 11% increase, and find 2,000 more people with high-risk polyps in their bowel, allowing doctors to remove them before they ever turn into cancers.
Additionally, in early 2026, the NHS Cervical Screening Programme will be offering a self-testing kit to under-screened women, starting with those who are the most overdue for screening. This will help tackle deeply entrenched barriers that keep some away from screening.
These national-level changes will benefit people across England, including those living in the Buckingham and Bletchley constituency.
Asked by: Lord Moylan (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many patients have received CAR-T therapy for mantle cell lymphoma via the Cancer Drugs Fund; and what assessment has been made of the clinical outcomes for those patients.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
202 patients have received brexucabtagene autoleucel, a form of CAR-T therapy, for the treatment of mantle cell lymphoma via the Cancer Drugs Fund (CDF). This data is taken from NHS England’s prior approval system. The National Institute for Health and Care Excellence (NICE) is currently re-evaluating the evidence on clinical outcomes collected through its use in the CDF in its ongoing re-evaluation of brexucabtagene autoleucel.
NICE published final draft guidance on 24 December 2025 in which it was not able to recommend brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had two or more lines of systemic treatment that included a Bruton's tyrosine kinase inhibitor. This is because the extent of brexucabtagene autoleucel’s clinical benefit is uncertain. There are also uncertainties in the economic model because there is not enough evidence to tell if the cancer can be ‘cured’ in people having brexucabtagene autoleucel and it is not known how long people live after having brexucabtagene autoleucel. The cost-effectiveness estimates are also substantially above the range that NICE considers an acceptable use of National Health Service resources. NICE has not yet published final guidance and stakeholders have recently had an opportunity to appeal NICE’s recommendations.
The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
Asked by: Samantha Niblett (Labour - South Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has had discussions with NICE on its Final Draft Guidance which does not recommend CAR-T therapy for relapsed or refractory Mantle Cell Lymphoma.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including in relation to the development of guidance on individual products.
NICE develops its recommendations on new medicines independently on the basis of a thorough assessment of the available evidence and through extensive engagement with interested parties. NICE is currently re-evaluating the CAR-T therapy brexucabtagene autoleucel (Tecartus) to determine whether it can be recommended for routine National Health Service use, taking into account real-world evidence generated through its use in the Cancer Drugs Fund.
Asked by: Caroline Johnson (Conservative - Sleaford and North Hykeham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the severity modifier on recent NICE recommendations on blood cancer treatments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Since the introduction of the severity modifier, the National Institute for Health and Care Excellence has approved 27 out of 28 blood cancer medicines it evaluated, reflecting an approval rate of 96%. Of these topics, a severity weighting was applied in nine topics.
Asked by: Caroline Johnson (Conservative - Sleaford and North Hykeham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure access to CAR-T therapy for mantle cell lymphoma patients who previously have been ineligible under the cancer drugs fund following NICE's most recent decision.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Decisions on whether new medicines should be routinely funded by the National Health Service in England are made by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of their costs and benefits. NICE is currently re-evaluating brexucabtagene autoleucel (Tecartus) to determine whether it can be recommended for routine NHS use, taking into account real-world evidence generated through its use in the Cancer Drugs Fund.
NICE has been unable to recommend the treatment in the final draft guidance, which is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11545/documents
This is because the available evidence does not suggest that brexucabtagene autoleucel is value for money in this population. Final guidance has not yet been published and the period to appeal NICE’s final draft recommendations closed on 19 January.
In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.
Asked by: Paul Davies (Labour - Colne Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the forthcoming National Cancer Plan will contain measures to ensure patients with blood cancer can access lifesaving and cutting-edge new therapies via the NHS.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan, to be published in the coming weeks, will set out in more detail how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology. The National Cancer Plan will have patients at its heart and will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as prevention, and research and innovation. It will seek to improve every aspect of cancer care to better the experience and outcomes for people with cancer, including improving access to lifesaving and cutting-edge new treatment.
Research is crucial in tackling cancer, which is why the Government invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority. For example, the NIHR supported the development of an immunotherapy for patients with an aggressive form of leukaemia, which was approved for routine use in the National Health Service by the National Institute for Health and Care Excellence in November 2025.
Asked by: Stuart Andrew (Conservative - Daventry)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the time taken for leukaemia diagnosis; and whether his Department has made an assessment of the potential implications for its policies of the findings of Leukaemia UK’s Count Us In campaign.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan will seek to improve outcomes for all cancers, including non-stageable cancers such as leukaemia. The Department remains committed to the early diagnosis of cancer and to improving outcomes for patients. However, we recognise that there is more to be done to ensure that patients with harder to stage cancers, such as blood cancer, receive fast and early diagnoses.
The National Health Service is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.
We have engaged extensively with Cancer 52 and other cancer charities, including Leukaemia UK to inform development of the National Cancer Plan, which will be published shortly. We have listened to concerns about existing early diagnosis targets and considered the feasibility of adopting new metrics to track progress, including suggestions from stakeholders that we track emergency presentation. Further details on our approach to early diagnosis, including how we can improve outcomes for rarer cancers, will be set out in due course.